Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
Sponsor: Mineralys Therapeutics Inc.
Listed as NCT05968430, this PHASE3 trial focuses on Hypertension and remains ongoing. Sponsored by Mineralys Therapeutics Inc., it has been updated 24 times since 2023, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
24 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Enrolling By Invitation PHASE3
▶ Show 19 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Enrolling By Invitation PHASE3
Status: Recruiting → Enrolling By Invitation
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
Phase: PHASE2/PHASE3 → PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jul 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mineralys Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .